All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
2013 — 8 Books and Research Papers Citing DrugPatentWatch
Gupta, H., & Babu, R. J. (2013). Transdermal delivery: product and patent update. Recent Patents on Drug Delivery & Formulation, 7(3), 232–241.
This review examines recent advancements in transdermal drug delivery systems, focusing on novel formulations and their associated patents. The authors highlight innovations aimed at improving drug permeation, stability, and patient compliance.
Samanen, J. (2013). The structure and business of biopharmaceutical companies including the management of risks and resources. In Introduction to Biological and Small Molecule Drug Development (pp. 1–20). Elsevier.
Samanen provides an overview of the organizational structure of biopharmaceutical companies, emphasizing the integration of research, development, and commercialization processes. The chapter discusses risk management strategies and resource allocation critical to drug development.
Serrano, D. R., Ballesteros, M. P., et al. (2013). Amphotericin B formulations–the possibility of generic competition. Pharmaceutical Patents, 2(3), 211–221.
This article analyzes various formulations of Amphotericin B, a critical antifungal agent, and evaluates the potential for generic competition. The authors discuss patent strategies and regulatory pathways influencing market entry.
Sylvester, K., Rocchio, M., Beik, N., & Fanikos, J. (2013). Biosimilars: an emerging category of biologic drugs for emergency medicine practitioners. Current Emergency and Hospital Medicine Reports, 1(2), 82–89.
The authors discuss the rise of biosimilars in the pharmaceutical market, focusing on their implications for emergency medicine. They review regulatory considerations, clinical applications, and economic factors influencing biosimilar adoption.
Finsterer, J., & Frank, M. (2013). Repurposed drugs in metabolic disorders. Current Topics in Medicinal Chemistry, 13(3), 291–307.
This review explores the potential of repurposing existing drugs for the treatment of metabolic disorders. The authors examine clinical evidence, mechanisms of action, and regulatory challenges associated with drug repurposing.
Israel, D. S., Krishnachaitanya, K., et al. (2013). RP-HPLC method for the estimation of tamsulosin and solifenacin in bulk and its dosage forms. International Journal of Pharmaceutical Sciences and Research, 4(8), 3030–3036.
The authors present a validated reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of tamsulosin and solifenacin in pharmaceutical formulations. The method is optimized for accuracy and precision.
Das, D. (2013). Formulation and technology transfer studies on antifungal injection. Search ProQuest.
This research focuses on the formulation development and technology transfer processes for an antifungal injectable drug. The study addresses challenges in scaling up production and ensuring consistent quality across different manufacturing sites.
Yokoya, J. M. C. (2013). Análise enantiosseletiva da fluvastatina em plasma por eletroforese capilar. [Capillary electrophoresis enantioselective analysis of fluvastatin in plasma]. Tese de doutorado, Universidade de São Paulo.
Yokoya's doctoral thesis investigates the enantioselective analysis of fluvastatin in plasma using capillary electrophoresis. The study aims to improve the understanding of the pharmacokinetics of fluvastatin's enantiomers.
